142 related articles for article (PubMed ID: 10984260)
1. Growth hormone therapy in young children with Down syndrome and a clinical comparison of Down and Prader-Willi syndromes.
Annerén G; Tuvemo T; Gustafsson J
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S87-91. PubMed ID: 10984260
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone therapy for Prader-Willi and Down syndromes: a post-modern medical dilemma.
Lantos JD
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S93-4. PubMed ID: 10984261
[TBL] [Abstract][Full Text] [Related]
3. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency.
Schmidt H; Bechtold S; Schwarz HP
Eur J Med Res; 2000 Jul; 5(7):307-10. PubMed ID: 10903191
[TBL] [Abstract][Full Text] [Related]
4. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.
Lindgren AC; Ritzén EM
Acta Paediatr Suppl; 1999 Dec; 88(433):109-11. PubMed ID: 10626558
[TBL] [Abstract][Full Text] [Related]
5. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
Fillion M; Deal C; Van Vliet G
J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
[TBL] [Abstract][Full Text] [Related]
8. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment.
Angulo MA; Castro-Magana M; Lamerson M; Arguello R; Accacha S; Khan A
Am J Med Genet A; 2007 Jul; 143A(13):1456-61. PubMed ID: 17567883
[TBL] [Abstract][Full Text] [Related]
9. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.
Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
Acta Paediatr Suppl; 1997 Nov; 423():60-2. PubMed ID: 9401542
[TBL] [Abstract][Full Text] [Related]
10. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome.
Hauffa BP
Acta Paediatr Suppl; 1997 Nov; 423():63-5. PubMed ID: 9440907
[TBL] [Abstract][Full Text] [Related]
11. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
Eiholzer U; Schlumpf M; Nordmann Y; l'Allemand D
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1441-4. PubMed ID: 11837497
[TBL] [Abstract][Full Text] [Related]
12. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome.
Obata K; Sakazume S; Yoshino A; Murakami N; Sakuta R
J Pediatr Endocrinol Metab; 2003 Feb; 16(2):155-62. PubMed ID: 12713251
[TBL] [Abstract][Full Text] [Related]
13. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
[TBL] [Abstract][Full Text] [Related]
14. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
[TBL] [Abstract][Full Text] [Related]
15. Maladaptive behavior in children with Prader-Willi syndrome, Down syndrome, and nonspecific mental retardation.
Dykens EM; Kasari C
Am J Ment Retard; 1997 Nov; 102(3):228-37. PubMed ID: 9394132
[TBL] [Abstract][Full Text] [Related]
16. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.
Tauber M; Barbeau C; Jouret B; Pienkowski C; Malzac P; Moncla A; Rochiccioli P
Horm Res; 2000; 53(6):279-87. PubMed ID: 11146368
[TBL] [Abstract][Full Text] [Related]
17. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10.
Eiholzer U; Meinhardt U; Rousson V; Petrovic N; Schlumpf M; l'Allemand D
Am J Med Genet A; 2008 Apr; 146A(7):873-80. PubMed ID: 18257095
[TBL] [Abstract][Full Text] [Related]
18. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.
Kuppens RJ; Mahabier EF; Bakker NE; Siemensma EP; Donze SH; Hokken-Koelega AC
Orphanet J Rare Dis; 2016 Nov; 11(1):153. PubMed ID: 27852283
[TBL] [Abstract][Full Text] [Related]
19. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.
Festen DA; Wevers M; Lindgren AC; Böhm B; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Jun; 68(6):919-25. PubMed ID: 18031326
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
